

ADVANCED COURSE PROGRAMME

Biomarkers for Precision Medicine

**ESMO
ADVANCED COURSE**

**SINGAPORE
9-10 OCTOBER 2022**

Chairs:

Kohei Shitara, Japan

Albrecht Stenzinger, Germany

ESMO ADVANCED COURSE PROGRAMME

BIOMARKERS FOR PRECISION MEDICINE

9-10 October 2022
Singapore

CO-CHAIRS:

Kohei Shitara, Japan
Albrecht Stenzinger, Germany

SPEAKERS:

Catherine Alix-Panabières, France
Federica Di Nicolantonio, Italy
Anand D. Jeyasekharan, Singapore
Daniel Kazdal, Germany
Jeeyun Lee, South Korea
Caterina Marchiò, Italy
Clara Montagut Viladot, Spain

Yoshiaki Nakamura, Japan
Yutaka Suzuki, Japan
Daniel S. W. Tan, Singapore
David S. P. Tan, Singapore
Takayuki Yoshino, Japan
Alex H. Wagner, United States
Lori J. Wirth, United States

LEARNING OBJECTIVES

- To acknowledge that an increasing number of therapeutics that require biomarkers testing are available for clinical use or are in an advanced phase of clinical development
- To understand how different technologies can be used for biomarker testing depending on the nature of the biomarker and the availability of biological samples
- To draw attention to the increasing use of large panels for comprehensive genomic profiling raises issues on data interpretation that require a multidisciplinary approach
- To obtain in-depth understanding of how monitoring the molecular evolution of the disease might allow the identification of resistance mechanisms and the development of more effective therapeutic strategies
- To understand that the identification of germline variants requires the activation of genetic counselling programs for patients and their families

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano, Switzerland
Email: courses@esmo.org
www.esmo.org



Sunday, 9 October 2022

9:00-9:10 **Welcome and introduction**

10' Welcome and Learning Objectives Introduction
Kohei Shitara, JP and Albrecht Stenzinger, DE

9:10-10:00 **Session 1 – Gene fusions**

20' Technical aspects
Daniel Kazdal, DE

20' Clinics (NTRK, RET, ROS1, FGFR2, NRG1, etc,...)
Lori J. Wirth, US

10' Discussion

10:00-10:30 Coffee break

10:30-11:20 **Session 2 – Homologous Repair Deficiency**

20' Technical aspects and definition
Anand D. Jeyasekharan, SG

20' Clinics (Ovarian, mPCA, PDAC,...)
David S. P. Tan, SG

10' Discussion

11:20-12:10 **Session 3 – Emerging technologies on AI and IO**

20' Leveraging AI to maximize value of digital pathology
Caterina Marchiò, IT

20' Understanding the emerging role of single cells genomics
Yutaka Suzuki, JP

10' Discussion

12:10-13:10 Lunch

13:10-14:00 **Session 4 – Liquid biopsy**

20' Technical aspects for CTCs and nucleic acid
Catherine Alix-Panabières, FR

20' Clinics (trials most importantly)
Clara Montagut Viladot, ES

10' Discussion

14:00-15:15 **Session 5 – Molecular tumour board (ESCAT criteria, performance data from molecular guided trials)**

20' Functional interpretation of variants
Alex H. Wagner, US

- 20' Clinical variant interpretation
Daniel S. W. Tan, SG
- 20' Organisation and role of the molecular tumour board
Albrecht Stenzinger, DE
- 15' Discussion

15:15-15:45 *Coffee break*

15:45-16:35 **Session 6 – Clinical trials (design, performance, emerging data...)**

- 20' SCRUM-Japan MONSTAR-SCREEN
Takayuki Yoshino, JP
- 20' VIKTORY Umbrella trial
Jeeyun Lee, KR
- 10' Discussion

17:00 *Networking Cocktail Reception*

Monday, 10 October 2022

9:00-12:30 **Workshop sessions**

Three parallel workshop sessions with 20 delegates in each group (delegates will attend all sessions on a rotation basis)

- 15' Introduction based on clinical cases presented by speakers
- 40' Discussion
- 5' Break (speakers will move from one room to the other)

Workshop 1
60' Interactive Molecular Tumour Board
Albrecht Stenzinger, DE
Daniel S. W. Tan, SG

Workshop 2
60' Interactive Practical Session: Clinical cases in assay challenges interpretation with discussion after each question
Federica Di Nicolantonio, IT

Workshop 3
60' Interpreting clinical trial data / How to achieve drug approval
Yoshiaki Nakamura, JP

11:00-11:30 *Coffee break*

11:30-12:30 **Workshops continuation**

12:30-13:00 **Plenary session: Feedback on the workshops from each group**

13:00-13:15 **Synthesis and wrap-up**

13:15-14:15 *Lunch*